Altay Therapeutics, Inc., a biotechnology company focused on small molecule inhibitors of transcription factors, announced the completion of a US$37 million Series A financing. The round was co-led by Sound Bioventures and HealthCap, with participation from Fountain Healthcare Partners, Biogen New Ventures, Pappas Capital, and Global BioAccess Fund. Proceeds are intended to advance DX5057, the company's lead oral DUX4 inhibitor, through Phase 1 and Phase 2 proof-of-concept trials for facioscapulohumeral muscular dystrophy (FSHD).
Funding Details and Investor Support
The Series A round was co-led by Sound Bioventures and HealthCap. New investors in the financing included Fountain Healthcare Partners, Biogen New Ventures, Pappas Capital, and Global BioAccess Fund. Four directors joined Altay's board in connection with the round: Ester Sklarsky of Sound Bioventures, Carl Kilander of HealthCap, Aidan King of Fountain Healthcare Partners, and Chelsea Johnson of Biogen New Ventures.
Capital Use and Clinical Milestones
Altay will use the financing to accelerate development of DX5057 through Phase 1 and Phase 2 proof-of-concept clinical trials in patients with FSHD. The clinical program will explore DUX4-related biomarkers and muscle function. The company expects a Phase 1 safety study to initiate in the first quarter of 2027, ahead of later-stage proof-of-concept work.
DX5057 Mechanism and Differentiation
DX5057 is an orally administered small molecule designed to bind double homeobox 4, or DUX4, and inhibit its function. By reducing downstream DUX4-regulated gene and protein expression, the candidate is expected to act systemically and distribute freely to affected muscles. Altay states that this approach can inhibit DUX4 deeply, which may help preserve muscle before loss becomes irreversible.
FSHD Context and Preclinical Evidence
FSHD is one of the most common inherited muscular dystrophies and is characterized by progressive skeletal muscle weakness and atrophy. The disease typically involves facial, scapular, and humeral muscles before extending to the trunk and lower extremities, and there are currently no approved disease-modifying therapies. In nonclinical pharmacology studies including a transgenic mouse model expressing human DUX4, DX5057 reduced DUX4-associated activity and downstream gene expression, reduced markers of muscle injury, and preserved disease-relevant muscle function.
Executive Commentary
James Breitmeyer, M.D., Ph.D., Chief Executive Officer of Altay, said that there are no disease-modifying therapies approved for FSHD and that the patient community needs a durable, practical solution. He described DX5057 as an oral medicine that acts systemically to shut down DUX4 at its source. Ester Sklarsky of Sound Bioventures added that Altay has delivered an oral small molecule candidate on its way into clinical development.
About Altay Therapeutics
Altay Therapeutics is a biotechnology company developing novel small-molecule inhibitors of transcription factors. In addition to DX5057, the company is advancing a STAT3 inhibitor and an ETS family inhibitor with potential across several cancers. Its proprietary discovery platform identifies allosteric binding pockets on transcription factors previously believed to be undruggable and uses AI modeling and in silico docking to identify small-molecule antagonists.
The US$37 million Series A positions Altay to advance what could become the first oral DUX4 inhibitor for FSHD into clinical testing. With backing from life sciences investors and early support from organizations such as SOLVE FSHD, the company is moving toward a Phase 1 safety study expected in the first quarter of 2027. That milestone could offer new hope for patients living with a progressive and currently untreatable muscular dystrophy.